AMRN Amarin Corp

RNS Number:8068B
Amarin Corporation Plc
09 August 2007







                             AMARIN CORPORATION PLC





LONDON, United Kingdom, August 9, 2007 Amarin Corporation plc ("Amarin" or
"Company") announces, in accordance with the UK Financial Services Authority's
Disclosure and Transparency Rules (the "Disclosure and Transparency Rules"),
that the Company's issued share capital as of today's date consists of
97,766,470 ordinary shares with voting rights, which represents the total number
of voting rights in the Company. 200,797 of these shares are held in treasury.



This figure may be used by shareholders as the denominator for the calculations
by which they will determine if they are required to notify an interest in, or a
change to an interest in, the share capital of the Company under the Disclosure
and Transparency Rules.



About Amarin

Amarin is committed to improving the lives of patients suffering from diseases
of the central nervous system.  Our goal is to be a leader in the research,
development and commercialization of novel drugs that address unmet patient
needs.



Amarin's core development pipeline includes, in addition to Miraxion for several
therapeutic indications, four other key development programs in Parkinson's
disease, epilepsy seizures, memory and cognition and our proprietary
pre-clinical combinatorial lipid program.



Amarin has its primary stock market listing in the U.S. on NASDAQ ("AMRN") and
secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"),
respectively.



For press releases and other corporate information, visit the Amarin website at
www.amarincorp.com.  Information on our website does not form part of this press
release.



Contacts:

Amarin
+44 (0) 207 907 2442

Rick Stewart
Chief Executive Officer

Alan Cooke
President & Chief Financial Officer

investor.relations@amarincorp.com



Investors:

Lippert/Heilshorn & Associates, Inc.                       +1 212 838 3777

Kim Golodetz

Anne Marie Fields



Media:

Powerscourt                                                                +44
(0) 207 250 1446

Rory Godson

Victoria Brough



Broker:

Davy

Ivan Murphy
+353 (0) 1 679 6363

Fergal Meegan



Ends.












This announcement has been issued through the Companies Announcement Service of



                            The Irish Stock Exchange








                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

ISEDGGGRGLLGNZM

Amarin (LSE:AMRN)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025

Amarin (LSE:AMRN)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025